Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
New UC Center for Alzheimer's and Neurodegenerative Diseases Research to advance dementia research, treatment and education
July 14, 2026
The University of Cincinnati and UC Health are launching the Center for Alzheimer's and Neurodegenerative Diseases Research (CANDR) to advance dementia research, clinical care and brain health education.
UC students organize free health clinic in community
July 13, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
Ohio ranked No. 1 for business by CNBC
July 10, 2026
Ohio is CNBC’s No. 1 Top State for Business in 2026. The University of Cincinnati helps fuel that success through co-op, innovation, talent development and close collaboration with the state.